Technologies

Potential as Coagulation-inhibiting Medical Agent

Patients suffering from these symptoms and diseases are given coagulation-inhibiting substances to stimulate the body’s own coagulation-inhibiting enzymes, such as antithrombin. Various anti-coagulants, such as heparin, are used in prophylaxis and therapy as well as during operations in order to inhibit blood coagulation. As the agents used so far have a number of side effects, alternative antithrombin co-factors are in great demand in the pharmaceutical and medical sector.

Scientists of the Institute of Nanotechnology (INT), in cooperation with the University of Murcia, Spain, have now found a new candidate agent that may possibly be better suited for application to diabetes patients and persons suffering from sugar allergy.